Last reviewed · How we verify
dextran and hypromellose
dextran and hypromellose is a Artificial tear / Ocular lubricant Small molecule drug developed by University of Campinas, Brazil. It is currently FDA-approved for Dry eye syndrome / Keratoconjunctivitis sicca, Ocular surface lubrication and protection. Also known as: Lacribell.
Dextran and hypromellose form a viscous ophthalmic solution that lubricates and protects the ocular surface by mimicking natural tears.
Dextran and hypromellose are used in eye care products, including Tears Naturale Forte and liposic, to manage conditions such as dry eye disease, Sjögren's syndrome, and conjunctivitis. The exact mechanism of action for these substances is unknown, but they are used in various eye care products to address different eye-related conditions.
At a glance
| Generic name | dextran and hypromellose |
|---|---|
| Also known as | Lacribell |
| Sponsor | University of Campinas, Brazil |
| Drug class | Artificial tear / Ocular lubricant |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Dextran is a polysaccharide that increases tear film viscosity and provides lubrication, while hypromellose (hydroxypropyl methylcellulose) is a cellulose derivative that enhances tear film stability and reduces evaporation. Together, these polymers create a protective barrier on the cornea and conjunctiva, alleviating symptoms of dry eye by maintaining moisture and reducing friction.
Approved indications
- Dry eye syndrome / Keratoconjunctivitis sicca
- Ocular surface lubrication and protection
Common side effects
- Transient blurred vision
- Eye irritation or discomfort
- Mild conjunctival hyperemia
Key clinical trials
- Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose (PHASE3)
- Corneal Thickness Changes in Patient Undergoing Dry Eye Managment (NA)
- Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction (NA)
- Hyperopic LASIK With Crosslinking Versus Standard LASIK (NA)
- Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ? (NA)
- Effect of Nursing Care on Prevention of Dry Eye (NA)
- Corneal Lesions in Intensive Care Unit (ICU) Clinical Trial for Proposing Interventions and Evaluating Outcomes of Nursing in the Adult Intensive Care Center Clinical Trial for Proposing Interventions and Evaluating Outcomes of Nursing in the Adult Intensive Care Center (NA)
- A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- dextran and hypromellose CI brief — competitive landscape report
- dextran and hypromellose updates RSS · CI watch RSS
- University of Campinas, Brazil portfolio CI
Frequently asked questions about dextran and hypromellose
What is dextran and hypromellose?
How does dextran and hypromellose work?
What is dextran and hypromellose used for?
Who makes dextran and hypromellose?
Is dextran and hypromellose also known as anything else?
What drug class is dextran and hypromellose in?
What development phase is dextran and hypromellose in?
What are the side effects of dextran and hypromellose?
Related
- Drug class: All Artificial tear / Ocular lubricant drugs
- Manufacturer: University of Campinas, Brazil — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Dry eye syndrome / Keratoconjunctivitis sicca
- Indication: Drugs for Ocular surface lubrication and protection
- Also known as: Lacribell
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing